Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Calgary, Calgary, Alberta, Canada.
Laryngoscope. 2014 Sep;124(9):2007-12. doi: 10.1002/lary.24630. Epub 2014 Mar 11.
OBJECTIVES/HYPOTHESIS: Disease-specific reductions in patient productivity can lead to substantial economic losses to society. The purpose of this study was to: 1) define the annual productivity cost for a patient with refractory chronic rhinosinusitis (CRS) and 2) evaluate the relationship between degree of productivity cost and CRS-specific characteristics.
Prospective, multi-institutional, observational cohort study.
The human capital approach was used to define productivity costs. Annual absenteeism, presenteeism, and lost leisure time was quantified to define annual lost productive time (LPT). LPT was monetized using the annual daily wage rates obtained from the 2012 U.S. National Census and the 2013 U.S. Department of Labor statistics.
A total of 55 patients with refractory CRS were enrolled. The mean work days lost related to absenteeism and presenteeism were 24.6 and 38.8 days per year, respectively. A total of 21.2 household days were lost per year related to daily sinus care requirements. The overall annual productivity cost was $10,077.07 per patient with refractory CRS. Productivity costs increased with worsening disease-specific QoL (r = 0.440; p = 0.001).
Results from this study have demonstrated that the annual productivity cost associated with refractory CRS is $10,077.07 per patient. This substantial cost to society provides a strong incentive to optimize current treatment protocols and continue evaluating novel clinical interventions to reduce this cost.
目的/假设:患者生产力的特定疾病下降可能导致社会的重大经济损失。本研究的目的是:1)定义难治性慢性鼻-鼻窦炎(CRS)患者的年度生产力成本,2)评估生产力成本与 CRS 特定特征之间的关系。
前瞻性、多机构、观察性队列研究。
采用人力资本法来定义生产力成本。量化每年的旷工、工作效率低下和失去闲暇时间,以确定每年失去的生产时间(LPT)。使用 2012 年美国国家普查和 2013 年美国劳工部统计数据获得的年度日工资率来对 LPT 进行货币化。
共纳入 55 例难治性 CRS 患者。与旷工和工作效率低下相关的平均工作天数分别为每年 24.6 和 38.8 天。每年因日常鼻窦护理需求而损失的家庭天数总计为 21.2 天。难治性 CRS 患者的整体年度生产力成本为每位患者 10077.07 美元。生产力成本随着疾病特异性 QoL 的恶化而增加(r = 0.440;p = 0.001)。
本研究结果表明,难治性 CRS 相关的年度生产力成本为每位患者 10077.07 美元。这对社会来说是一个巨大的成本,这为优化当前的治疗方案提供了强大的动力,并继续评估新的临床干预措施来降低这一成本。